Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Metab Eng. 2016 Dec 26;43(Pt B):208–217. doi: 10.1016/j.ymben.2016.12.010

Fig 5. LKB1 deficiency sensitizes cells to inhibition of Complex I and glutaminase.

Fig 5

(A) Cell viability after treatment with vehicle, BPTES (10 μM), or phenformin (1mM or 2mM) after 48 hours treatment. (B–C) Glutamate and α-ketoglutarate (αKG) labeling from [U-13C5]glutamine after treatment with vehicle or phenformin (50 μM) in A549 (B) and H460 (C) vec. and +LKB1 cells. (D) Cell viability after treatment with vehicle, phenformin (1mM) and BPTES (10μM), or phenformin (2mM) and BPTES (10μM) in A549 and H460 vec. and +LKB1 cells. (E) Coefficient of drug interaction (CDI) values for A549 and H460 vec. and +LKB1 cells treated with either phenformin (1mM) and BPTES (10μM) or phenformin (2mM) and BPTES (10μM).